Yukon Metals Corp press release

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MP, GATO and CABA

2022-04-12

CSE - Canadian National Stock Exchange · Gold · Copper · Molybdenum · Silver · Lead · Zinc · Barium · Cadmium · Tin · Antimony · Arsenic · Cobalt · Nickel · Iron · Selenium · Tellurium · Scandium · Bismuth · Platinum · Lanthanum · Yttrium · Rare Earth Elements · Canada

NEW YORK, NY / ACCESSWIRE / April 12, 2022 /The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

MP Materials Corp. f/k/a Fortress Value Acquisition Corp. (NYSE:MP) _Class Period:_May 1, 2020 - February 2, 2022 _Lead Plaintiff Deadline:_April 25, 2022

According to the complaint, MP Materials Corp. f/k/a Fortress Value Acquisition Corp. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Fortress Value Acquisition Corp. ("FVAC") had overstated its due diligence efforts and expertise with respect to identifying target companies to acquire; (ii) FVAC performed inadequate due diligence into Legacy MP Materials prior to the business combination, or else ignored significant red flags regarding, inter alia, Legacy MP Materials' management, compliance policies, and Mountain Pass's profitability; (iii) as a result, the Company's future business and financial prospects post-business combination were overstated; (iv) MP Materials engaged in an abusive transfer price manipulation scheme with a related party in the People's Republic of China to artificially inflate the Company's profits; (v) MP Materials' ore at the Mountain Pass Rare Earth Mine and Processing Facility was not economically viable to harvest for rare earth metals; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in MP: https://www.kleinstocklaw.com/pslra-1/mp-materials-corp-f-k-a-fortress-value-acquisition-corp-loss-submission-form?id=25890&from=1

Gatos Silver, Inc. (NYSE:GATO) This lawsuit is on behalf of persons and entities that purchased or otherwise acquired Gatos: (a) common stock pursuant and/or traceable to documents issued in connection with the Company's initial public offering conducted on or about October 28, 2020; and/or (b) securities between October 28, 2020 and January 25, 2022, inclusive. _Lead Plaintiff Deadline:_April 25, 2022

The GATO lawsuit alleges that throughout the class period, Gatos Silver, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the technical report for Gatos's primary mine, the Cerro Los Gatos deposit, contained certain errors; (2) among other things, the mineral reserves had been overestimated by as much as 50%; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in GATO: https://www.kleinstocklaw.com/pslra-1/gatos-silver-inc-loss-submission-form?id=25890&from=1

Cabaletta Bio, Inc. (NASDAQ:CABA) This lawsuit is on behalf of persons and entities that purchased or otherwise acquired: (a) Cabaletta common stock pursuant and/or traceable to documents issued in connection with the Company's initial public offering conducted on or about October 24, 2019; and/or (b) Cabaletta securities between October 24, 2019 and December 13, 2021, both dates inclusive. _Lead Plaintiff Deadline:_April 29, 2022

According to the complaint, Cabaletta Bio, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) top-line data of the Phase 1 Clinical Trial indicated that Cabaletta's lead product candidate, DSG3-CAART, had, among other things, worsened certain participants' disease activity scores and necessitated additional systemic medication to improve disease activity after DSG3-CAART infusion; (ii) accordingly, DSG3-CAART was not as effective as the Company had represented to investors; (iii) therefore, the Company had overstated DSG3-CAART's clinical and/or commercial prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in CABA: https://www.kleinstocklaw.com/pslra-1/cabaletta-bio-inc-loss-submission-form?id=25890&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT: J. Klein, Esq. Empire State Building 350 Fifth Avenue 59th Floor New York, NY 10118 jk@kleinstocklaw.com Telephone: (212) 616-4899 Fax: (347) 558-9665 www.kleinstocklaw.com

SOURCE: The Klein Law Firm

View source version on accesswire.com: https://www.accesswire.com/697205/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-MP-GATO-and-CABA